Omeprazole + SyrSpend SF Alka and Pexidartinib Hydrochloride
Determining the interaction of Omeprazole + SyrSpend SF Alka and Pexidartinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with proton pump inhibitors (PPIs) may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: Concomitant use of pexidartinib with proton pump inhibitors should be avoided. If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:GENERALLY AVOID: Coadministration with proton pump inhibitors (PPIs) may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: Concomitant use of pexidartinib with proton pump inhibitors should be avoided. If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: omeprazole
Brand name: FIRST Omeprazole, Omeprazole + SyrSpend SF Alka, Prilosec, Prilosec OTC, Zegerid>, Prilosec, Prilosec OTC
Synonyms: Omeprazole
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Omeprazole + SyrSpend SF Alka-Pfizerpen
- Omeprazole + SyrSpend SF Alka-Pharaon Tea
- Omeprazole + SyrSpend SF Alka-Pharmorubicin Pfs
- Omeprazole + SyrSpend SF Alka-Phazyme
- Omeprazole + SyrSpend SF Alka-Phazyme Liquid Gas Relief, Maximum Strength
- Omeprazole + SyrSpend SF Alka-Phena-Plus
- Pexidartinib Hydrochloride-Omeprazole and sodium bicarbonate
- Pexidartinib Hydrochloride-Omeprazole and Sodium Bicarbonate Capsule
- Pexidartinib Hydrochloride-Omeprazole and Sodium Bicarbonate Capsules
- Pexidartinib Hydrochloride-Omeprazole and Sodium Bicarbonate Powder Packets
- Pexidartinib Hydrochloride-Omeprazole Delayed-Release Capsules
- Pexidartinib Hydrochloride-Omeprazole Delayed-Release Capsules and Tablets (OTC)